Cargando…
Role of Nucleobindin-2 in the Clinical Pathogenesis and Treatment Resistance of Glioblastoma
Glioblastoma (GBM) stands as the most prevalent primary malignant brain tumor, typically resulting in a median survival period of approximately thirteen to fifteen months after undergoing surgery, chemotherapy, and radiotherapy. Nucleobindin-2 (NUCB2) is a protein involved in appetite regulation and...
Autores principales: | Lin, I-Cheng, Chang, Chih-Hui, Chong, Yoon Bin, Kuo, Shih-Hsun, Cheng, Yu-Wen, Lieu, Ann-Shung, Tseng, Tzu-Ting, Lin, Chien-Ju, Tsai, Hung-Pei, Kwan, Aij-Lie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572158/ https://www.ncbi.nlm.nih.gov/pubmed/37830634 http://dx.doi.org/10.3390/cells12192420 |
Ejemplares similares
-
miR-3059-3p Regulates Glioblastoma Multiforme Radiosensitivity Enhancement through the Homologous Recombination Pathway of DNA Repair
por: Cheng, Yu-Wen, et al.
Publicado: (2022) -
Hyperbaric Oxygen Therapy Adjuvant Chemotherapy and Radiotherapy through Inhibiting Stemness in Glioblastoma
por: Yuen, Chun-Man, et al.
Publicado: (2023) -
Galectin-3 Mediates Tumor Progression in Astrocytoma by Regulating Glycogen Synthase Kinase-3β Activity
por: Tsai, Hung-Pei, et al.
Publicado: (2023) -
Induction of Mitosis Delay and Apoptosis by CDDO-TFEA in Glioblastoma Multiforme
por: Tsai, Tai-Hsin, et al.
Publicado: (2021) -
High expression of GSKIP is associated with poor prognosis in meningioma
por: Cheng, Yu-Wen, et al.
Publicado: (2022)